FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients
February 16th 2024This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.
Read More
AI Algorithm Demonstrates Ability to Predict the Efficacy of Sertraline in Patients With Depression
February 12th 2024Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.
Read More
Black Patients More Likely to Experience Delays in Multiple Myeloma Treatment Initiation
February 2nd 2024Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.
Read More
Study: Hydroxyurea Reduces Severe, Invasive Infections by 60% in Children with Sickle Cell Disease
February 1st 2024The findings suggest that further research on additional intervention methods and expanding access to hydroxyurea in Africa could benefit young patients with sickle cell disease.
Read More
FDA Approves IgG-Hyaluronidase Recombinant for the Treatment of Adult Patients With CIDP
January 16th 2024Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.
Read More